What’s in Akorn Inc (NASDAQ:AKRX) After Decline in Shorted Shares?

The stock of Akorn Inc (NASDAQ:AKRX) registered a decrease of 16.36% in short interest. AKRX’s total short interest was 7.30M shares in December as published by FINRA. Its down 16.36% from 8.73M shares, reported previously. With 2.50M shares average volume, it will take short sellers 3 days to cover their AKRX’s short positions. The short interest to Akorn Inc’s float is 7.78%.

The stock decreased 3.81% or $0.17 during the last trading session, reaching $4.29. About 3.39M shares traded. Akorn, Inc. (NASDAQ:AKRX) has declined 86.27% since December 11, 2017 and is downtrending. It has underperformed by 86.27% the S&P500.

Akorn, Inc., a specialty generic pharmaceutical company, develops, makes, and markets specialized generic and branded pharmaceuticals, over-the-counter drug products, and animal health products in the United States and internationally. The company has market cap of $538.36 million. The firm operates in two divisions, Prescription Pharmaceuticals and Consumer Health. It currently has negative earnings. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics.

Akorn, Inc. (NASDAQ:AKRX) Ratings Coverage

Among 2 analysts covering Akorn (NASDAQ:AKRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akorn had 2 analyst reports since October 17, 2018 according to SRatingsIntel. PiperJaffray upgraded Akorn, Inc. (NASDAQ:AKRX) on Wednesday, October 17 to “Overweight” rating. Piper Jaffray maintained it with “Buy” rating and $900 target in Tuesday, November 27 report.

More notable recent Akorn, Inc. (NASDAQ:AKRX) news were published by: Schaeffersresearch.com which released: “Akorn Options Volume Explodes After Fresenius Court Ruling – Schaeffers Research” on December 07, 2018, also Nasdaq.com with their article: “Here’s Why Akorn Pharmaceuticals Is Sinking Today – Nasdaq” published on December 06, 2018, Streetinsider.com published: “Akorn (AKRX) CEO to Leave After Negative Delaware Supreme Court Decision – StreetInsider.com” on December 10, 2018. More interesting news about Akorn, Inc. (NASDAQ:AKRX) were released by: Seekingalpha.com and their article: “Microcaps tops midday movers – Seeking Alpha” published on December 07, 2018 as well as Seekingalpha.com‘s news article titled: “Marinus Pharmaceuticals and CorMedix among healthcare gainers; MiMedx Group leads the losers – Seeking Alpha” with publication date: December 06, 2018.

Akorn, Inc. (NASDAQ:AKRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.